The state of Minnesota currently has 22 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
North American Prodromal Synucleinopathy Consortium Stage 2
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
A Study of Caregiver Connections Via Technology in Dementia
Recruiting
This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes. Dementia caregivers often assume greater caregiving burden than do non-dementia caregivers, and the caregiving duration tends to be longer. Many caregivers do not have the adequate support they need. Peer-to-peer support has been shown to improve quality of life, more engagement... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Caregiver Stress, Dementia, Alzheimer Disease, Lewy Body Dementia, Parkinson Disease Dementia, Frontotemporal Dementia
Intranasal Insulin in Parkinson's Disease
Recruiting
This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.
Gender:
All
Ages:
Between 41 years and 89 years
Trial Updated:
04/01/2024
Locations: HealthPartners Neuroscience Center, Saint Paul, Minnesota
Conditions: Parkinson Disease
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
03/28/2024
Locations: Mayo Clinic, Rochester, Minnesota +2 locations
Conditions: Parkinson's Disease
Neuroplasticity in Parkinson's Disease
Recruiting
The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions... Read More
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
03/25/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson, Parkinson Disease
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
03/11/2024
Locations: Neurology, Golden Valley, Minnesota
Conditions: Parkinson Disease
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
03/01/2024
Locations: Struthers Parkinson's Center, Golden Valley, Minnesota
Conditions: Parkinson's Disease
Study in Parkinson Disease of Exercise
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
02/20/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson Disease
Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst
Recruiting
This study will help us better understand how the brain works in people with Parkinson's disease (PD). PD is a brain disease that gets worse over time, and affects over 10 million people world-wide. A common treatment for PD is Deep Brain Stimulation (DBS). To improve DBS therapy for PD, we need a deeper understanding of how the different parts of the brain work together in PD, and how this relates to movement and thinking problems that people with PD experience. We may be able to use the resul... Read More
Gender:
Female
Ages:
21 years and above
Trial Updated:
02/14/2024
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson Disease
Sleep-specific DBS Therapy in Parkinson's Disease
Recruiting
Sleep-wake disturbances are a major factor associated with reduced quality of life of individuals with Parkinson's disease (PD), a progressive neurological disorder affecting millions of people in the U.S and worldwide. The brain mechanisms underlying these sleep disorders, and the effects of therapeutic interventions such as deep brain stimulation on sleep-related neuronal activity and sleep behavior, are not well understood. Results from this study will provide a better understanding of the br... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
02/14/2024
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Dystonia
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Recruiting
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in u... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/08/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Parkinson's Disease Psychosis
Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
Recruiting
Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Parkinson Disease, Movement Disorders